Literature DB >> 15371934

Mesenteric adenitis and portal vein thrombosis due to Fusobacterium nucleatum.

Roland El Braks1, Florence Harnois, Nevine Boutros, David Fallik, Jean Roudie, Claude Smadja, Jocelyne De Laveaucoupet, Jean-Claude Chaput, Sylvie Naveau, Philippe Mathurin.   

Abstract

We report the first description of portal and mesenteric vein thrombosis associated with suppurative mesenteric adenitis in a 71-year-old woman. The bacterium detected in mesenteric lymph nodes was Fusobacterium nucleatum, an anaerobic Gram-negative bacillus. Our patient had a clinical syndrome of pharyngitis and fever preceding portal vein thrombosis. Abdominal symptoms improved with antibiotics and anticoagulant therapy. This location of F. nucleatum in mesenteric lymph nodes provides an interesting insight into the occurrence of septic thrombosis in the portal vein following pharyngo-tonsillar infection.

Entities:  

Mesh:

Year:  2004        PMID: 15371934     DOI: 10.1097/00042737-200410000-00019

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

1.  Fusobacterium nucleatum infection mimicking metastatic cancer.

Authors:  Armin Rashidi; Sami G Tahhan; Mark W Cohee; Benjamin M Goodman
Journal:  Indian J Gastroenterol       Date:  2012-08-09

2.  Fusobacterium necrophorum--beyond Lemierres syndrome.

Authors:  Lokesh Shahani; Nancy Khardori
Journal:  BMJ Case Rep       Date:  2011-11-15

3.  Serum immunoglobulin G antibody titer to Fusobacterium nucleatum is associated with unfavorable outcome after stroke.

Authors:  H Nishi; N Hosomi; K Ohta; S Aoki; M Nakamori; T Nezu; H Shigeishi; T Shintani; T Obayashi; K Ishikawa; N Kinoshita; Y Shiga; M Sugiyama; H Ohge; H Maruyama; H Kawaguchi; H Kurihara
Journal:  Clin Exp Immunol       Date:  2020-03-24       Impact factor: 4.330

Review 4.  Portal vein thrombosis despite anticoagulation in a person with diabetes.

Authors:  J H Schweigart; A Klotsas; S Schelenz; K Dhatariya
Journal:  J R Soc Med       Date:  2005-04       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.